KROS — Keros Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.09bn
- $1.76bn
- $0.15m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -12.3 | -45.4 | -58.7 | -105 | -153 |
Depreciation | |||||
Non-Cash Items | 2.85 | 5.91 | 12.3 | 19.6 | 30.3 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -6.72 | 2.27 | -16.1 | 14.3 | -2.65 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -16 | -36.9 | -62.1 | -70.1 | -125 |
Capital Expenditures | -0.271 | -0.294 | -1.02 | -1.24 | -2.46 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | -0.271 | -0.294 | -1.02 | -1.24 | -2.46 |
Financing Cash Flow Items | 0 | -3.2 | 0 | -0.087 | -0.094 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 0.014 | 296 | 28.6 | 120 | 179 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -16.3 | 259 | -34.6 | 49 | 52 |